-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

1706 Results from the Cohort-Expansion Stage of a Phase I Trial of Tinostamustine Monotherapy in Advanced Hodgkin Lymphoma (HL), Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma (MM) (NCT02576496)

Program: Oral and Poster Abstracts
Session: 624. Hodgkin Lymphomas and T/NK Cell Lymphomas: Clinical and Epidemiological: Poster I
Hematology Disease Topics & Pathways:
Research, clinical trials, Hodgkin lymphoma, Non-Biological therapies, Lymphomas, Chemotherapy, Clinical Research, T Cell lymphoma, Diseases, Therapies, Lymphoid Malignancies, Myeloid Malignancies
Saturday, December 9, 2023, 5:30 PM-7:30 PM

Anna Maria Sureda Balari, MD, PhD1, Herve Ghesquieres, MD, PhD2*, Franck Morschhauser, phd3, Pim Mutsaers, MD4*, Enrique M Ocio, MD, PhD5, Tomas Janik6*, Nick Manamley6*, Kasia Hilgier, MD6* and Pier Luigi Zinzani, MD, PhD7

1Clinical Hematology, Instituto Catalán de Oncología, L'Hospitalet De Llobregat, IDIBELL, Universitat de Barcelona, Barcelona, Spain
2Hematology Department, Hopital Lyon Sud - HCL, Lyon, France
3Hôpital Claude Huriez, Lille, France
4Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands
5Hospital Universitario Marques de Valdecilla, IDIVAL, Santander, Spain
6Mundipharma Research Ltd, Cambridge, United Kingdom
7Institute of Hematology "Seràgnoli" University of Bologna, Bologna, Italy

Background

Tinostamustine, a novel alkylating deacetylase inhibitor, improves drug access to cancer cell DNA strands, breaks them and counteracts damage repair. Tinostamustine was well tolerated, with signals of efficacy, during the dose-escalation stage of a Phase I study in patients with relapsed/refractory (R/R) haematological malignancies (Zinzani et al. HemaSphere 2019;3(S1):102:PF300) and for patients with HL in the cohort-expansion stage (Ghesquières et al. Blood 2021;138(S1):2472; Sureda et al. Blood 2022;140(S1):3696).

Aims

We report safety and efficacy findings from patients with advanced haematological malignancies including HL, cutaneous T-cell lymphoma (CTCL), peripheral T-cell lymphoma (PTCL), T-cell prolymphocytic leukaemia (T-PLL) and MM treated with tinostamustine in the expansion cohorts of a Phase I study.

Methods

Patients with advanced haematological malignancies, for whom no standard treatment with proven clinical benefit was available or recommended, were recruited to receive the recommended Phase II dose of tinostamustine. Patients with HL must have received ≥2 lines of prior therapy, CTCL 1–4 prior standard systemic therapies, PTCL >1 prior line of combination therapy, T-PLL ≥1 prior line of therapy and MM ≥1 prior systemic therapy. Adverse events (AEs) were assessed for severity using US National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE; version 4.03, June 2010; for QTc prolongations CTCAE version 5.0 was used). Treatment-related AEs, fatal AEs, serious adverse events (SAEs), and AEs resulting in trial discontinuation were recorded. Primary efficacy objectives were to estimate the overall response rate (ORR; complete response [CR] + partial response [PR]) and clinical benefit rate (CBR; CR + PR + stable disease ≥4 cycles [SD]) for each cohort and to evaluate the safety of tinostamustine. Secondary efficacy variables included progression-free survival (PFS) and overall survival (OS); all outcomes were evaluated from Cycle 3 until progression or toxicity.

Results

48 patients with advanced haematological malignancies were enrolled to the study and received treatment with tinostamustine (HL, n=20; CTCL, n=13; PTCL, n=8; T-PLL, n=1; MM, n=6; Table). Patients with HL, CTCL, PTCL and T-PLL received 50 mg/m2 (1 patient), 80 mg/m2 (7 patients) and 100 mg/m2 (34 patients) over 60 minutes on Day 1 of a 21-day cycle; patients with MM: 60 mg/m2 over 60 minutes on Day 1 and Day 15 of a 28-day cycle. Patients received a median of 3.5 (range 1–12) cycles of tinostamustine. No unexpected AEs were observed. Treatment-emergent AEs (TEAEs) occurred in 46/48 (95.8%) patients (500 events), with 28 patients experiencing 90 events ≥Grade 3. Gastrointestinal AEs were observed in 33/48 patients, the majority of which were nausea or vomiting. Haematological AEs, including thrombocytopenia, anaemia and neutropenia, occurred in 27/48 patients. Serious TEAEs considered related to tinostamustine occurred in 11 patients with HL or CTCL (Table) and included thrombocytopenia (n=3) and infusion-related reaction (n=1); one patient with CTCL experienced a fatal TEAE of decreased appetite. Overall, 22/48 (45.8%) patients discontinued due to progressive disease and 13/48 (21.6%) discontinued due to AEs. In the 46 patients included in the efficacy analysis, ORR was 30.4% (95% confidence interval [CI]: 17.7%, 45.8%) and CBR 52.2% (95% CI: 36.9%, 67.1%). 4 patients achieved a CR (2 patients with HL, 2 CTCL), 10 a PR (5 HL, 4 CTCL, 1 PTCL) and 14 SD (4 HL, 4 CTCL, 3 PTCL, 3 MM). Median PFS was 4.3 months (95% CI: 2.7, 6.6 months; HL, 3.8 [2.2, 9.4] months; CTCL, 7.3 [3.2, not estimable (NE)] months; PTCL, 2.6 [1.4, NE] months; T-PLL, 0.5 [NE, NE] months; MM, 2.4 [1.4, NE] months;). Median OS was 10.3 (95% CI: 2.2, NE) months for PTCL, 5.6 (95% CI: NE, NE) months for T-PLL and not estimable for HL, CTCL and MM.

Conclusions

Results from expansion cohorts further demonstrate that tinostamustine has manageable tolerability in patients with advanced haematological malignancies with no unexpected AEs. The principal TEAEs were haematological and gastrointestinal. An ORR of 30.4% and a median progression-free survival of 4.3 months were observed, revealing signals of efficacy in this heavily pre-treated patient population for whom no other standard therapy with proven clinical benefit was available or recommended.

Funding: Mundipharma Research Limited and Purdue Pharma, LP

Disclosures: Sureda Balari: Sanofi: Consultancy, Honoraria; Roche: Honoraria; Takeda: Consultancy, Honoraria, Research Funding, Speakers Bureau; BMS/Celgene: Consultancy, Honoraria, Research Funding; MSD: Honoraria; Janssen: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Amgen: Honoraria; Gilead Kite: Honoraria; Gilead: Consultancy; Alexion: Honoraria. Ghesquieres: Gilead, Roche, Bristol Myers Squibb, AbbVie, Novartis: Honoraria; Gilead, Roche: Consultancy. Morschhauser: BMS: Consultancy, Other: Advisory Board; Novartis: Consultancy, Other: Advisory Board; AbbVie: Consultancy, Other: Advisory Board; Janssen: Honoraria; Gilead: Consultancy, Other: Advisory Board; Celgene: Other: Advisory Board; Roche: Consultancy, Honoraria, Other: Advisory Board; Incyte: Other: Advisory Board; Epizyme: Other: Advisory Board; Genmab: Consultancy, Other: Advisory Board. Mutsaers: GlaxoSmithKline: Consultancy; AstraZeneca: Research Funding. Ocio: Janssen: Consultancy, Honoraria, Speakers Bureau; Karyopharm: Consultancy; Menarini: Consultancy; Oncopeptides: Consultancy, Honoraria, Research Funding; Pfizer: Consultancy, Honoraria; Regeneron: Honoraria; Sanofi: Consultancy, Honoraria; GSK: Consultancy, Honoraria, Research Funding; BMS: Consultancy, Honoraria; Amgen: Consultancy, Honoraria; Abbvie: Consultancy; Takeda: Consultancy, Honoraria. Janik: Mundipharma Research Ltd: Current Employment. Manamley: Mundipharma Research Ltd: Current Employment. Hilgier: Mundipharma Research Ltd: Consultancy. Zinzani: SECURA BIO: Membership on an entity's Board of Directors or advisory committees; SANDOZ: Membership on an entity's Board of Directors or advisory committees; EUSAPHARMA: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; ADC THERAPEUTICS: Membership on an entity's Board of Directors or advisory committees; BEIGENE: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; CELLTRION: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; BMS: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; INCYTE: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; TAKEDA: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; NOVARTIS: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; KYOWA KIRIN: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; MSD: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; SERVIER: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; ROCHE: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; GILEAD: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; ASTRAZENECA: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; JANSSEN-CILAG: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau.

*signifies non-member of ASH